{
    "Trade/Device Name(s)": [
        "STA\u00ae Liatest\u00ae D-Di"
    ],
    "Submitter Information": "Diagnostica Stago",
    "510(k) Number": "K162227",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040882"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DAP"
    ],
    "Summary Letter Date": "November 7, 2016",
    "Summary Letter Received Date": "November 9, 2016",
    "Submission Date": "05 August 2016",
    "Regulation Number(s)": [
        "21 CFR 864.7320"
    ],
    "Regulation Name(s)": [
        "Fibrinogen/fibrin degradation products assay"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "D-dimer"
    ],
    "Specimen Type(s)": [
        "Venous plasma"
    ],
    "Specimen Container(s)": [
        "3.2% sodium citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "STA-R\u00ae",
        "STA Compact\u00ae",
        "STA Satellite\u00ae"
    ],
    "Method(s)/Technology(ies)": [
        "Immuno-turbidimetric assay"
    ],
    "Methodologies": [
        "Turbidimetric detection",
        "Antigen-antibody agglutination"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for STA Liatest D-Di immuno-turbidimetric assay for quantitative D-dimer measurement in plasma to exclude PE and DVT",
    "Indications for Use Summary": "Quantitative determination of D-dimer in venous plasma, used with a clinical pretest probability model to exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) in outpatients suspected of PE or DVT",
    "fda_folder": "Hematology"
}